p.95 抽出テキスト

gender-optimized diagnostic strategies. J Am Coll Cardiol 2006;47:S4–20. https://doi. org/10.1016/j.jacc.2005.01.072 78. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009; 361:858–67. https://doi.org/10.1056/NEJMoa0900428 79. Keller T, Zeller T, Peetz D, Tzikas S, Roth A, Czyz E, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med 2009;361:868–77. https:// doi.org/10.1056/NEJMoa0903515 80. Nelson SD, Kou WH, Annesley T, de Buitleir M, Morady F. Significance of ST segment depression during paroxysmal supraventricular tachycardia. J Am Coll Cardiol 1988;12: 383–7. https://doi.org/10.1016/0735-1097(88)90410-x 81. Imrie JR, Yee R, Klein GJ, Sharma AD. Incidence and clinical significance of ST segment depression in supraventricular tachycardia. Can J Cardiol 1990;6:323–6. https://doi.org/ 10.1016/j.amjmed.2017.01.002 82. Riva SI, Della Bella P, Fassini G, Carbucicchio C, Tondo C. Value of analysis of ST segment changes during tachycardia in determining type of narrow QRS complex tachycardia. J Am Coll Cardiol 1996;27:1480–5. https://doi.org/10.1016/0735-1097(96) 00013-7 83. Rivera S, De La Paz Ricapito M, Conde D, Verdu M, Roux J, Paredes F. The retrograde P-wave theory: explaining ST segment depression in supraventricular tachycardia by retrograde AV node conduction. Pacing Clin Electrophysiol 2014;37:1100–5. https:// doi.org/10.1111/pace.12394 84. Mercik J, Radziejewska J, Pach K, Zawadzki G, Zyśko D, Gajek J, et al. ST-segment depression in atrioventricular nodal reentrant tachycardia: important finding or just an artifact? Medicine (Baltimore) 2022;101:e31806. https://doi.org/10.1097/md. 0000000000031806 85. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2019;41:255–323. https://doi.org/10. 1093/eurheartj/ehz486 86. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J 2023;44:4043–140. https://doi.org/10.1093/eurheartj/ehad192 87. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, et al. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points—a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016;37:1944–58. https:// doi.org/10.1093/eurheartj/ehw152 88. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol 2013;61:1146–56. https://doi. org/10.1016/j.jacc.2012.12.023 89. Rossello X. Lifetime risk estimation in atherosclerotic cardiovascular disease: where inflammation meets lipoprotein(a). J Am Coll Cardiol 2021;78:1095–6. https://doi.org/ 10.1016/j.jacc.2021.07.035 90. Boffa MB, Stranges S, Klar N, Moriarty PM, Watts GF, Koschinsky ML. Lipoprotein(a) and secondary prevention of atherothrombotic events: a critical appraisal. J Clin Lipidol 2018;12:1358–66. https://doi.org/10.1016/j.jacl.2018.08.012 91. Malick WA, Goonewardena SN, Koenig W, Rosenson RS. Clinical trial design for lipoprotein(a)-lowering therapies: JACC focus seminar 2/3. J Am Coll Cardiol 2023;81: 1633–45. https://doi.org/10.1016/j.jacc.2023.02.033 92. Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J 2022;43: 3925–46. https://doi.org/10.1093/eurheartj/ehac361 93. Lopes NH, da Silva Paulitsch F, Pereira A, Garzillo CL, Ferreira JF, Stolf N, et al. Mild chronic kidney dysfunction and treatment strategies for stable coronary artery disease. J Thorac Cardiovasc Surg 2009;137:1443–9. https://doi.org/10.1016/j.jtcvs.2008.11.028 94. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ 2010;341:c4986. https://doi. org/10.1136/bmj.c4986 95. Nitsch D, Grams M, Sang Y, Black C, Cirillo M, Djurdjev O, et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013;346:f324. https://doi.org/10.1136/bmj.f324 96. Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009; 361:2538–47. https://doi.org/10.1056/NEJMoa0805299 97. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304:2503–12. https://doi.org/10.1001/jama. 2010.1768 98. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Šaltytė Benth J, et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013;61:1240–9. https://doi.org/ 10.1016/j.jacc.2012.12.026 99. van Holten TC, Waanders LF, de Groot PG, Vissers J, Hoefer IE, Pasterkamp G, et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One 2013;8:e62080. https://doi. org/10.1371/journal.pone.0062080 100. Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL, et al. Troponin and cardiac events in stable ischemic heart disease and diabetes. N Engl J Med 2015; 373:610–20. https://doi.org/10.1056/NEJMoa1415921 101. Laufer EM, Mingels AM, Winkens MH, Joosen IAPG, Schellings MWM, Leiner T, et al. The extent of coronary atherosclerosis is associated with increasing circulating levels of high sensitive cardiac troponin T. Arterioscler Thromb Vasc Biol 2010;30:1269–75. https://doi.org/10.1161/ATVBAHA.109.200394 102. Madsen DM, Diederichsen ACP, Hosbond SE, Gerke O, Mickley H. Diagnostic and prognostic value of a careful symptom evaluation and high sensitive troponin in patients with suspected stable angina pectoris without prior cardiovascular disease. Atherosclerosis 2017;258:131–7. https://doi.org/10.1016/j.atherosclerosis.2016.11.030 103. Adamson PD, Hunter A, Madsen DM, Shah ASV, McAllister DA, Pawade TA, et al. High-sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes 2018;11:e004227. https://doi.org/10.1161/circoutcomes.117.004227 104. Januzzi JL Jr, Suchindran S, Coles A, Ferencik M, Patel MR, Hoffmann U, et al. High-sensitivity troponin I and coronary computed tomography in symptomatic outpatients with suspected cad: insights from the PROMISE trial. JACC Cardiovasc Imaging 2019;12:1047–55. https://doi.org/10.1016/j.jcmg.2018.01.021 105. Vavassori C, Cipriani E, Colombo GI. Circulating microRNAs as novel biomarkers in risk assessment and prognosis of coronary artery disease. Eur Cardiol 2022;17:e06. https://doi.org/10.15420/ecr.2021.47 106. Hoogeveen RM, Pereira JPB, Nurmohamed NS, Zampoleri V, Bom MJ, Baragetti A, et al. Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention. Eur Heart J 2020;41:3998–4007. https://doi.org/10.1093/eurheartj/ ehaa648 107. Ibrahim NE, Januzzi JL Jr, Magaret CA, Gaggin HK, Rhyne RF, Gandhi PU, et al. A clinical and biomarker scoring system to predict the presence of obstructive coronary artery disease. J Am Coll Cardiol 2017;69:1147–56. https://doi.org/10.1016/j.jacc.2016.12.021 108. Hilvo M, Meikle PJ, Pedersen ER, Tell GS, Dhar I, Brenner H, et al. Development and validation of a ceramide- and phospholipid-based cardiovascular risk estimation score for coronary artery disease patients. Eur Heart J 2020;41:371–80. https://doi.org/10. 1093/eurheartj/ehz387 109. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836–43. https://doi.org/10.1056/nejm200003233421202 110. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387–97. https://doi.org/10.1056/ NEJMoa032804 111. Sinning JM, Bickel C, Messow CM, Schnabel R, Lubos E, Rupprecht HJ, et al. Impact of C-reactive protein and fibrinogen on cardiovascular prognosis in patients with stable angina pectoris: the AtheroGene study. Eur Heart J 2006;27:2962–8. https://doi.org/10. 1093/eurheartj/ehl362 112. Jia RF, Li L, Li H, Cao X-J, Ruan Y, Meng S, et al. Meta-analysis of C-reactive protein and risk of angina pectoris. Am J Cardiol 2020;125:1039–45. https://doi.org/10.1016/j. amjcard.2020.01.005 113. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973–9. https://doi.org/10.1056/nejm199704033361401 114. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635–41. https://doi.org/10.1056/nejm1995030933 21003 115. De Luca G, Verdoia M, Cassetti E, Schaffer A, Cavallino C, Bolzani V, et al. High fibrinogen level is an independent predictor of presence and extent of coronary artery disease among Italian population. J Thromb Thrombolysis 2011;31:458–63. https://doi. org/10.1007/s11239-010-0531-z 116. Ndrepepa G, Braun S, King L, Fusaro M, Keta D, Cassese S, et al. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol 2013;111:804–10. https://doi.org/10.1016/j.amjcard.2012.11.060 117. Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham study. JAMA 1987;258:1183–6. https://doi.org/10. 1001/jama.1987.03400090067035 118. Appiah D, Schreiner PJ, MacLehose RF, Folsom AR. Association of plasma γ′ fibrinogen with incident cardiovascular disease: the Atherosclerosis Risk in Communities (ARIC)

ESC Guidelines                                                                                                                                                                                          3509

Downloaded from academic.oup.com/eurheartj/article/45/36/3415/7743115 by guest on 07 October 2026